Nandini C. Patel
Pfizer (United States)(US)PRX Research
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, HER2/EGFR in Cancer Research, Computational Drug Discovery Methods, Neuroscience and Neuropharmacology Research, COVID-19 Clinical Research Studies
Most-Cited Works
- → An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19(2021)1,855 cited
- → Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271(2008)380 cited
- → Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened(2011)159 cited
- → Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans(2022)113 cited
- → Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration(2019)98 cited
- → A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19(2024)61 cited
- → In Vitro–In Vivo Extrapolation of Key Transporter Activity at the Blood–Brain Barrier(2019)46 cited
- → Novel γ-secretase modulators: a review of patents from 2008 to 2010(2011)45 cited
- → Discovery of SARS-CoV-2 papain-like protease (PL pro ) inhibitors with efficacy in a murine infection model(2024)42 cited
- → The Discovery of a Novel Phosphodiesterase (PDE) 4B-Preferring Radioligand for Positron Emission Tomography (PET) Imaging(2017)36 cited